5005 McConnell Avenue
Los Angeles, CA 90066
United States
310 665 2928
https://www.armatapharma.com
Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 66
Nombre | Título | Paga | Ejecutado | Año de nacimiento |
---|---|---|---|---|
Dr. Deborah L. Birx M.D. | CEO & Director | 536,43k | N/A | 1957 |
Mr. Richard Rychlik | VP, Corporate Controller & Principal Financial Officer | 302,35k | N/A | 1956 |
Dr. Mina Pastagia M.D., MS | Chief Medical Officer | 463,75k | N/A | 1975 |
Mr. Peter Hubbard | Vice President of Operations | N/A | N/A | N/A |
Dr. Pierre Kyme Ph.D. | Senior Vice President of Business & Corporate Development | N/A | N/A | N/A |
Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has research collaboration agreement with Merck Sharp & Dohme Corp. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is headquartered in Los Angeles, California.
El ISS Governance QualityScore de Armata Pharmaceuticals, Inc., a día N/A, es N/A. Las puntuaciones base son Auditoría: N/A; Tablero: N/A; Derechos de los accionistas: N/A; Compensación: N/A.